Review of poor responders to intravitreal ranibizumab for age-related macular degeneration Toushi Toibana 1 , Takashi Katome 1 , Takeshi Naito 1 , Yoshinori Mitamura 1 1Dept of Ophthalmol and Vis Neurosci, Inst of Health Biosci, The Univ of Tokushima Grad Sch pp.1709-1712
Published Date 2013/10/15
DOI https://doi.org/10.11477/mf.1410104943
  • Abstract
  • Look Inside
  • Reference

Abstract. Purpose:To present a review of cases who showed poor response to intravitreal ranibizumab for age-related macular degeneration(AMD). Cases and Method:This retrospective study was made on 28 eyes of 28 cases that received intravitreal ranibizumab or AMD in the past 18 months. As inclusion criteria, all the cases showed no improvement in visual acuity after treatment. They were evaluated regarding the type of AMD, size of the lesion, past history of treatment, and duration from onset to start of treatment. Cases that improved after the same treatment served as control. Results:The present series included higher rates of polypoid choroidal vasculopathy(PCV)and of retinal angiomatous proliferation(RAP)than the control group. The present series showed significantly higher values for greatest linear dimension(p<0.01)and longer duration between onset to start of treatment(p<0.01). Conclusion:Cases of PCV and RAP tended to show poor response to intravitreal ranibizumab. Response to treatment was poor in eyes with larger lesion or in cases treated after long interval from onset.

Copyright © 2013, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院